Total Payments
$3.0M
2024 Payments
$357,330
Companies
69
Transactions
3,305
Medicare Patients
475
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$1.9M (65.5%)
Consulting$666,493 (22.5%)
Travel$224,813 (7.6%)
Food & Beverage$75,729 (2.6%)
Research$44,503 (1.5%)
Education$7,067 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 605 | 62.8% |
| Consulting Fee | $666,493 | 161 | 22.5% |
| Travel and Lodging | $224,813 | 558 | 7.6% |
| Food and Beverage | $75,729 | 1,914 | 2.6% |
| Honoraria | $51,060 | 21 | 1.7% |
| Unspecified | $44,503 | 13 | 1.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $18,649 | 3 | 0.6% |
| Grant | $10,000 | 6 | 0.3% |
| Education | $7,067 | 24 | 0.2% |
Payments by Type
General
$2.9M
3,292 transactions
Research
$44,503
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $687,931 | 694 | $0 (2024) |
| EMD Serono, Inc. | $504,876 | 415 | $0 (2024) |
| Genentech USA, Inc. | $376,893 | 276 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $335,309 | 432 | $0 (2024) |
| GENZYME CORPORATION | $209,627 | 238 | $0 (2024) |
| Celgene Corporation | $178,064 | 181 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $127,841 | 81 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $94,804 | 108 | $0 (2024) |
| Horizon Therapeutics plc | $77,036 | 120 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $71,797 | 110 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $357,330 | 414 | EMD Serono, Inc. ($127,053) |
| 2023 | $309,635 | 387 | EMD Serono, Inc. ($125,513) |
| 2022 | $345,038 | 473 | EMD Serono, Inc. ($77,408) |
| 2021 | $217,914 | 339 | EMD Serono, Inc. ($63,866) |
| 2020 | $275,195 | 231 | Biogen, Inc. ($100,074) |
| 2019 | $524,414 | 456 | Biogen, Inc. ($129,966) |
| 2018 | $492,753 | 452 | Biogen, Inc. ($147,578) |
| 2017 | $433,521 | 553 | Biogen, Inc. ($143,837) |
All Payment Transactions
3,305 individual payment records from CMS Open Payments — Page 1 of 133
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,933.00 | General |
| Category: Neurology | ||||||
| 12/23/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,088.00 | General |
| Category: Neurology | ||||||
| 12/20/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $89.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/20/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $89.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Neurology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,618.00 | General |
| Category: Neuroscience | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Neurology | ||||||
| 12/16/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $136.82 | General |
| Category: Neurology | ||||||
| 12/16/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/16/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/14/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.50 | General |
| 12/12/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: Neurology | ||||||
| 12/12/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $10.86 | General |
| Category: Immune | ||||||
| 12/12/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $1.03 | General |
| Category: Neurology | ||||||
| 12/11/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $33.74 | General |
| 12/11/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $8.60 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.48 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Immune | ||||||
| 12/04/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: Neurology | ||||||
| 12/02/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,933.00 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| KESIMPTA Reserach Medical Writing/ Publication Support | Novartis Pharmaceuticals Corporation | $21,685 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $10,861 | 5 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,750 | 1 |
| An International Patient Survey to Assess Patients Preference for DMT Treatment Attributes in Multiple Sclerosis | F. Hoffmann-La Roche AG | $2,467 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $2,451 | 1 |
| An International Discrete Choice Experiment Assessing Patients' Preferences for Disease-modifying Therapy Attributes in Multiple Sclerosis | F. Hoffmann-La Roche AG | $1,292 | 1 |
| One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,289 | 2 |
| One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial | F. Hoffmann-La Roche AG | $707.93 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 6 | 160 | 11,964 | $1.9M | $485,466 |
| 2021 | 8 | 205 | 13,361 | $2.1M | $538,868 |
| 2020 | 3 | 110 | 127 | $29,447 | $8,161 |
Total Patients
475
Total Services
25,452
Medicare Billing
$1.0M
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 15 | 11,700 | $1.9M | $470,387 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 126 | $27,206 | $10,638 | 39.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 18 | 49 | $13,671 | $2,302 | 16.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $5,343 | $1,359 | 25.4% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 17 | 46 | $3,496 | $674.02 | 19.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 15 | 30 | $3,000 | $105.98 | 3.5% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2021 | 15 | 12,900 | $2.1M | $516,519 | 25.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 78 | 143 | $30,852 | $13,230 | 42.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 23 | 79 | $22,041 | $3,923 | 17.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $8,241 | $2,519 | 30.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2021 | 22 | 92 | $6,992 | $1,369 | 19.6% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 15 | 31 | $3,813 | $691.03 | 18.1% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 13 | 29 | $2,610 | $328.74 | 12.6% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2021 | 19 | 67 | $6,700 | $289.11 | 4.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 83 | 100 | $25,840 | $7,190 | 27.8% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 16 | 16 | $1,290 | $553.94 | 42.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 11 | $2,317 | $416.81 | 18.0% |
About Dr. Barry Hendin, MD
Dr. Barry Hendin, MD is a Neurology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447239231.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Hendin, MD has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $357,330 received in 2024. These payments were reported across 3,305 transactions from 69 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.9M).
As a Medicare-enrolled provider, Hendin has provided services to 475 Medicare beneficiaries, totaling 25,452 services with total Medicare billing of $1.0M. Data is available for 3 years (2020–2022), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Phoenix, AZ
- Active Since 01/11/2006
- Last Updated 10/20/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1447239231
Products in Payments
- Mavenclad (Drug) $318,562
- OCREVUS (Biological) $284,389
- TECFIDERA (Drug) $224,794
- ZEPOSIA (Drug) $187,439
- AUBAGIO (Drug) $166,079
- GILENYA (Drug) $150,173
- TYSABRI (Biological) $138,681
- VUMERITY (Drug) $134,921
- Ozanimod (Drug) $81,118
- UPLIZNA (Drug) $77,036
- KESIMPTA (Drug) $76,871
- MAVENCLAD (Drug) $72,450
- COPAXONE (Drug) $69,051
- Non-Covered Product (Drug) $57,018
- BRIUMVI (Drug) $56,048
- ACTHAR (Biological) $48,215
- Mavenclad (Biological) $42,682
- MAYZENT (Drug) $36,209
- UPLIZNA (Biological) $30,330
- Ocrevus (Biological) $28,173
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Phoenix
Maria Ospina, Md, MD
Neurology — Payments: $1.7M
Neurology $1.7M
Dr. Suraj Muley, Md, MD
Neurology — Payments: $1.5M
Neurology $1.5M
Steve Chung, M.d, M.D
Neurology — Payments: $993,222
Neurology $993,222
Shafeeq Ladha, M.d, M.D
Neurology — Payments: $712,796
Neurology $712,796
Lori Travis, Md, MD
Neurology — Payments: $705,788
Neurology $705,788
Dr. Jeffrey Gitt, D.o, D.O
Neurology — Payments: $669,966
Neurology $669,966